

Learner Notification

Society for Immunotherapy of Cancer
2023 Primer on Tumor Immunology and Cancer Immunotherapy
November 2, 2023
San Diego, CA

Acknowledgement of Financial Commercial Support

Incyte Corporation, Merck Sharp & Dohme LLC

Acknowledgement of In-Kind Commercial Support

No in-kind commercial support was received for this educational activity.

Satisfactory Completion

Learners must complete an evaluation form to receive a certificate of completion. If you need MOC credit, you also need to pass a posttest with a score of at least 80%. Your chosen sessions must be attended in their entirety. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

Joint Accreditation Statement



In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Society for Immunotherapy of Cancer. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Amedco Joint Accreditation #4008163

Physicians (ACCME) Credit Designation

Amedco LLC designates this live activity for a maximum of 6.75 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacists and Pharmacy Technicians (ACPE) Credit Designation

Amedco LLC designates this activity for a maximum of 6.75 knowledge-based CPE contact hours.

UAN(s): JA4008163-9999-23-238-L01-P / JA4008163-9999-23-238-L01-T

NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of your participation in the activity to meet the deadline for submission to CPE Monitor.

Nurses (ANCC) Credit Designation

Amedco LLC designates this activity for a maximum of 6.75 ANCC contact hours.

American Board of Internal Medicine (ABIM) MOC Credit



Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.75 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

You must request your certificate within 30 days of the activity to meet the deadline for submission to PARS. Credits are generally reported during the first week of each month for those who claimed during the month prior.

Objectives - After Attending This Program You Should Be Able To

1. Describe the key principles of cancer immunology and immunotherapy in the context of the cancer immunity cycle.
2. Review current approaches to immunotherapy including immune checkpoint blockade, vaccines, CAR-T cells, CAR-NK cells, activation of myeloid cells, modulation of tumor metabolism, T/NK cell adoptive transfer and bispecific antibodies.
3. Outline immune monitoring techniques as well as biomarker strategies and their role in trial design and patient selection.

4. Enhance scientific exchange with colleagues and collaborators on research and application of cancer immunotherapies to improve outcomes of patients with cancer.

Disclosure of Conflict of Interest

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1---6.2, 6.5)

All individuals in a position to control the content of CE are listed below.

First Name	Last Name	Commercial Interest: Relationship
Niroshana	Anandasabapathy	Shennon Pharam, Janssen, Immunitas, Verruca: Consultant/Advisor/Speaker, Moderna: Stock Shareholder
Kristin	Anderson	NA
Tullia	Bruno	Walking Fish Therapeutics, Kalivir: Advisory Board, Galvanize, Attivare, Mestag: Consultant
Susan	Bullman	AstraZeneca, Roche: Consultant/Advisor/Speaker
Beatriz	Carreno	NA
Lan	Coffman	Alkermes: Research Grant
Greg	Delgoffe	Kalivir, Century Therapeutics, 2seventybio, Astellas, Novasenta, Merck, Pfizer, BMS: Researcher, BlueSphere Bio, Kalivir, Century Therapeutics, Astellas/Universal Cells, RemplirBio, Novasenta: Consultant/Advisor/Speaker, RemplirBio, Novasenta: Stock Shareholder
Sangeeta	Goswami	NA
Lewis	Lanier	Atreca, Catamaran, Dragonfly, Drenbio, Edity, Hinge, IMIDomics, Inndura, Innovent, Mendus, Nkarta, Obsidian, SBI Bio: Consultant/Advisor/Speaker, Atreca, Nkarta: Stock Shareholder
Vivek	Narayan	Merck, Pfizer, Janssen, Regeneron, Bristol Myers Squibb, Tmunity Therapeutics: Researcher, Merck, Pfizer, Janssen, Regeneron, Myovant, Exelixis, Bristol Myers Squibb, AstraZeneca: Consultant/Advisor/Speaker
Keri	Schadler	Jazz Pharmaceutical: Researcher
Robert	Schreiber	Asher Biotherapeutics, Jounce Therapeutics: Other, Asher Biotherapeutics, Jounce Therapeutics, NGM Biopharmaceuticals, Sensei Biotherapeutics: Researcher, A2 Biotherapeutics, Arch Oncology, Asher Biotherapeutics, Codiak Biosciences, Glaxo SmithKline, Jounce Therapeutics, Meryx, NGM Biopharmaceuticals, Sensei Biotherapeutics, Bluesphere Bio: Consultant/Advisor/Speaker, A2 Biotherapeutics, Arch Oncology, Asher Biotherapeutics, Codiak Biothersciences, Jounce Therapeutics, NGM Biopharmaceuticals, Perkin Elmer Inc, Sensei Biotherapeutics: Stock Shareholder
Padmanee	Sharma	Achelois, Adaptive Biotechnologies, Affini-T, Apricity, Asher Bio, BioAtla LLC, BioNTech, Candel Therapeutics, Catalio, Carisma, Codiak Biosciences, Inc, C-Reveal Therapeutics, Dragonfly Therapeutics, Earli Inc, Enable Medicine, Glympse, Henlius/Hengenix, Hummingbird, ImaginAb, Infinity Pharma, InterVenn Biosciences, JSL Health, LAVA Therapeutics, Lytix Biopharma, Marker Therapeutics, Oncolytics, PBM Capital, Phenomic AI, Polaris Pharma, Sporos, Time Bioventures, Trained Therapeutix Discovery, Two Bear Capital, Xilis, Inc.: Consultant/Advisor/Speaker
Jo	Shultz	NA
Sumit	Subudhi	NA
Dario	Vignali	BMS, Novasenta, Tizona: Researcher, Novasenta, Tizona, , Trishula, Oncorus, Warewolf: Owner, Tizona, Warewolf, F-Star, Bicara, Apeximmune, T7/Imreg Bio, BMS, Incyte, G1 Therapeutics, Inzen Therapeutics: Consultant/Advisor, Speaker, BMS, Novasenta, Tizona: Royalties: BMS, Warewolf, Oncorus: Stock Shareholder
Michelle	Williams	NA
David	Wood	Pfizer: Stock Shareholder
Catherine	Wu	Pharmacyclics: Researcher, BioNTech: Equity Holder

How to Get Your Certificate

1. Go to <http://sitc.cmecertificateonline.com/>

2. Click on the **“2023 Primer on Tumor Immunology and Cancer Immunotherapy”** or **“2023 Primer on Tumor Immunology and Cancer Immunotherapy (ABIM MOC)”** link.
3. Evaluate the meeting and click the hyperlink provided on the last page to claim your credit certificate.
4. Save/Download/Print all pages of your certificate for your records.
5. If you lose your certificate, or need help, go to help.cmecertificateonline.com

Questions? Email Certificate@AmedcoEmail.com